Unraveling the regulatory role of intercellular communication in intestinal immune cells mediated by H₂ in sepsis recovery through single-cell RNA sequencing.
Yanhua Luo, Yajuan Zhao, Jinfeng Liu, Bin Liu, Zhimei Zhang, Yuan Jiang, Yaopeng Zhang, Xue-Ting Wang, Shilong Li, Nian Zhao, Xiaokang Li, Dong Xiong, Xue Zhao, Shaoqiang Wang, Weihang Zhang, Bao Lang · Journal of translational medicine · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, H₂ treatment significantly ameliorated intestinal injury, reduced epithelial barrier leakage (evidenced by decreased serum DAO and FITC-dextran), and suppressed systemic inflammation. scRNA-seq revealed that H₂ restored sepsis-induced perturbations in both B and T cell subsets. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in mice. H₂ treatment significantly ameliorated intestinal injury, reduced epithelial barrier leakage (evidenced by decreased serum DAO and FITC-dextran), and suppressed systemic inflammation. scRNA-seq revealed that H₂ restored sepsis-induced perturbations in both B and T cell subsets.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 2% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 2% source-reported H₂ gas concentration; 1 L/min H₂ flow (1000 mL/min H₂); reported treatment duration: 3 days. H₂ treatment significantly ameliorated intestinal injury, reduced epithelial barrier leakage (evidenced by decreased serum DAO and FITC-dextran), and suppressed systemic inflammation. scRNA-seq revealed that H₂ restored sepsis-induced perturbations in both B and T cell subsets. The authors concluded that the study elucidates that H₂ therapy alleviates sepsis by systemically reprogramming the intestinal immune micro environment at the single-cell level.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment. The source-reported hydrogen concentration was 2% source-reported H₂ gas concentration. The reported treatment duration was 3 days.
Limitations and Safety
Reported limitations: While the authors' scRNA-seq analysis robustly identified distinct transcriptomic shifts in intestinal immune sub-clusters, a methodological limitation of the current study is the reliance on macroscopic and downstream functional assays (e.g., ELISA, intestinal permeability, and histological scoring) rather than direct protein-level quantification. Safety information: The advantages of H₂ therapy for sepsis are multifaceted, centering on its anti-inflammatory and antioxidant properties, organ-protective effects, and high safety profile.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.